Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
31.32
+0.76 (2.49%)
Mar 17, 2026, 2:17 PM EDT - Market open

Capricor Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-22.2725.182.550.24
Revenue Growth (YoY)
--11.55%886.81%941.85%-21.06%
Gross Profit
-22.2725.182.550.24
Selling, General & Admin
23.6914.8712.8110.437.61
Research & Development
84.4549.9736.4521.8213.57
Total Operating Expenses
108.1464.8449.2632.2521.18
Operating Income
-108.14-42.56-24.08-29.7-20.94
Interest Income
6.262.21.730.520.06
Interest Expense
-3.05----
Other Non-Operating Income (Expense)
-0.11-0.110.060.160.86
Total Non-Operating Income (Expense)
3.12.11.790.680.92
Pretax Income
-105.04-40.47-22.29-29.02-20.02
Provision for Income Taxes
-0----
Net Income
-105.04-40.47-22.29-29.02-20.02
Net Income to Common
-105.04-40.47-22.29-29.02-20.02
Shares Outstanding (Basic)
4635272523
Shares Outstanding (Diluted)
4635272523
Shares Change (YoY)
31.97%31.52%9.06%6.34%48.28%
EPS (Basic)
-2.26-1.15-0.83-1.18-0.87
EPS (Diluted)
-2.26-1.15-0.83-1.18-0.87
Free Cash Flow
0-41.53-27.641.56-18.01
Free Cash Flow Per Share
--1.18-1.030.06-0.78
Gross Margin
-100.00%100.00%100.00%100.00%
Operating Margin
--191.13%-95.63%-1163.93%-8549.86%
Profit Margin
--181.71%-88.52%-1137.37%-8175.86%
FCF Margin
--186.50%-109.79%61.02%-7352.29%
EBITDA
-108.14-41.14-23.01-29.16-20.69
EBITDA Margin
--184.73%-91.39%-1143.04%-8449.54%
EBIT
-108.14-42.56-24.08-29.7-20.94
EBIT Margin
--191.13%-95.63%-1163.93%-8549.86%
Effective Tax Rate
0.00%0.00%0.00%0.00%0.00%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q